Participants

7 Hills Pharma
Absco Therapeutics
Alexandria Real Estate Equities
Alnylam Pharmaceuticals
Altoida
Aquilo Partners
Arc Fusion
Arcturus Therapeutics
Arrakis Therapeutics
AstraZeneca
Bectas Therapeutics
BIAL Biotech
Biogen
BiotechTV
Blackbird Laboratories
Bluejay Therapeutics
Breakthru Medicine
Broad Institute
Chiesi USA
Citizens Private Bank
Clayton Bio Communications
Corsera Health
DaCapo Brainscience
Definium Therapeutics
Delix Therapeutics
Delphia Therapeutics
DLA Piper
DUB Therapeutics
Eikoinizo Therapeutics
EMD Serono
EnPlusone Biosciences
Entact Bio
Entrada Therapeutics
Enveda

Evotec
Evvy
Flagship Pioneering
Flux Therapeutics
Gallop Oncology
GATC Health
Genepool Networks
General Proximity
Geron
GrayBella Capital
Grove BioPharma
Hevolution
Ipsen
Jefferson River Capital
Johnson & Johnson Innovation -
JJDC
Kynexis Therapeutics
Lafana Life Sciences
LB Pharmaceuticals
LIBRIS Innovations
Lily Ventures
Luminary Therapeutics
Lumira Ventures
Lytica Therapeutics
Martrisome Bio
MassBio
Merck
MResult
Merz Therapeutics
Monte Rosa Therapeutics

MResult
N=1 Collaborative
Neurvati Neurosciences
Neptune Bio
Neurosterix
Normunity
Novita Pharmaceuticals
Nucleate
NuCyRNA Therapeutics
Otsuka Pharmaceutical
OutSee
Oxford Finance
PathAI
Pretzel Therapeutics
ProFound Therapeutics
PxB Fund
Reverb Therapeutics
Q32 Bio
Sante
Satellite Bio
Seismic Therapeutics
Sidley
Spur Therapeutics
SpyBiotech
Syntis Bio
Tensor Bio
The Timmerman Report
Tiller Therapeutics
Two Bear Capital
USA Today
Versatope Therapeutics
Vertex Ventures HC
WilmerHale
Xilio Therapeutics